Drug Trial Radar · NCT07393451
A Multicenter Phase 2a Clinical Study to Evaluate SIM0278 in Subjects With Active Lupus Nephritis
Last checked: Nov 19, 2026Latest source record: Feb 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Mar 31, 2026
Primary completion
Mar 31, 2028
Study completion Aug 31, 2028
Sponsor
- Lead sponsor
- Simcere Pharmaceutical Co., LtdAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled multicenter clinical study to evaluate the efficacy, safety, and pharmacokinetics of SIM0278 in adult (18-75 years) subjects with active LN suitable for systemic therapy. Approximately 60 subjects with active LN are planned to be enrolled and randomized 1: 1 to SIM0278 or placebo. The study consists of 3 phases: screening, double-blind treatment, and safety follow-up.
Conditions
- Lupus Nephritis
Interventions
SIM0278 injectionDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of subjects achieving an overall renal response (complete renal response (CRR) + partial renal response (PRR)) at Week 52Time frame: At Week 52
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking Union Medical College Hospital
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.